References
- Furusaka T, Matsuda H, Saito T, Katsura Y, Ikeda M. Long-term observations and salvage operations on patients with T2N0M0 squamous cell carcinoma of the glottic larynx treated with radiation therapy alone. Acta Otolaryngol 2012;132:546–51.
- Sobin LH, Gospodarowicsz MK, Wittekind CH. 2009. TNM classification of malignant tumours. 7th edition. New York: Wiley-Blackwell. p 39–45.
- Harrap KR, Jones M, Wilkinson CR, Clink HM, Sparrow S, Mitchley BCV, 1980. Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In Prestayko AW, Crooke ST, Carter SK, editors. Cisplatin: current status and new developments. New York: Academic Press. p 193–212.
- Yoshizumi N, Fujiwara J, Yoshizaki A, Sato M, Sasaki R, Nishiya I. Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line. Hum Cell 1988;1:301–7.
- Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140–7.
- Jose RA, Kaplan S, Goldbirsch A, Sessa C, Brunner KW, Cavalli F. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 1984;2:297–304.
- Foster BJ, Clagett-Carr K, Leyland-Jones B, Hoth D. Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 1985;12(Suppl A):43–9.
- Ogawa M, Imajyo K, Horikoshi N, Inoue K, Mukaiyama T, Yamazaki H, A phase I study of carboplatin. Jpn J Cancer Chemother 1987;14(Pt I):1292–6.
- Kimura K, Kato T, Takamizawa H, Tari K, Suzuoki Y, Sekiba K, A phase I study of carboplatin. Oncologia 1988;21:88–94.
- Inuyama Y, Togawa K, Morita M, Takeoda S, Kaneko T, Takemiya S, Phase II study of carboplatin for head and neck cancer. Jpn J Cancer Chemother 1988;15:2131–8.
- Inoue H, Kida A, Suzuki M, Yoshida T, Furusaka T, Endo S, Concurrent carboplatin with radiotherapy in T2 laryngeal cancer. Head Neck Cancer 2002;28:223–30.
- Collins JM, Zaharko DS, Trites J, Trites J, Corsten G, Hart RD, Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rev 1985;70:73–80.
- Calvert AH, Nowell DR, Wada H, Takai Y, Yamada S. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.
- Jelliffe RW, Tukuda M, Mikami Y, Horiuchi C, Ishitoya J-I, Katori H. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604–5.
- Mlynarek A, Kost K, Gesser R. Radiotherapy versus surgery for early T1-T2 glottic carcinoma. J Otolaryngol 2006;35:413–19.
- Piccirillo IF, Wells CK, Sasaki CT, Feinstein AR. New clinical severity staging system for cancer of larynx. Five-year survival rates. Ann Otol Rhinol Laryngol 1994;103:83–92.
- Hafidh M, Tibbo J, Trites J, Trites J, Corsten G, Hart RD, Radiotherapy for T1 and T2 laryngeal cancer: the Dalhousie University experience. J Otolaryngol Head Neck Surg 2009;38:434–9.
- Taguchi T, Tukuda M, Mikami Y, Horiuchi C, Ishitoya J-I, Katori H. Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2N0M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol 2006;120:478–81.
- Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;4:5432–8.
- Breitbart WS, Holland JC. 1989. Head and neck cancer. In Holland JC, Rowland JH, editors. Handbook of psycho-oncology: psychological care of the patient with cancer. New York: Oxford University Press. p 232–9.